Anti-inflammatory cytokines

Chest

Volumn 117, Issue 4, 2000, Pages 1162-1172

  Opal, Steven M ^a,b   DePalo, Vera A ^a  

^a BROWN UNIVERSITY   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Anti inflammatory cytokines; Cytokines; Inflammation; Sepsis; Septic shock

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; PRIORITY JOURNAL;

EID: 0034090602     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.4.1162     Document Type: Article

References (109)

1. 1 Munoz C, Carlet J, Fitting C, et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88:1747-1754
2. 2 Kasai T, Inada K, Takakuwa T, et al. Anti-inflammatory cytokine levels in patients with septic shock. Res Commun Mol Pathol Pharmacol 1997; 98:34-42
3. 3 Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998; 16:457-499
4. 4 Döcke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by interferon gamma treatment. Nat Med 1997; 3:678-681
5. 5 Westendorp RGJ, Langermans JAM, Huizinga TWJ, et al. Genetic influence on cytokine production in fatal meningococcal disease. Lancet 1997; 349:170-173
6. 6 Donnelly SC, Strieter RM, Reid FT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fields of patients with the adult respiratory distress syndrome. Ann Intern Med 1996; 125:191-196
7. 7 Opal SM, Cross AS, Jhung J, et al. Potential hazards of combination immunotherapy in the treatment of experimental sepsis. J Infect Dis 1996; 173:1415-1421
8. 8 van de Poll T, Marchant A, van Deventer SJH. The role of interleukin-10 in the pathogenesis of bacterial infection. Clin Microbiol Infect 1997; 3:605-607
9. 9 Mosmann TR, Chenvinski H, Bond MW, et al. Two types of murine helper T-cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-2357
10. 10 Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol Today 1995; 16:374-379
11. 11 Zedler S, Bone RC, Baue AE, et al. T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med 1999; 27:66-72
12. 12 Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-2147
13. 13 Opal SM. Interleukin-1 receptor antagonist in sepsis. In: Bodmer M, Henderson W, eds. Therapeutic modulation of the cytokines. London, UK: CRC Press, 1996; 196-219
14. 14 Dinarello CA. Induction of interleukin-1 and interleukin-1 receptor antagonist. Semin Oncol 1997; 24(suppl):S9-81, S9-93
15. 15 Simms JE, Gayle MA, Slack JL, et al. Interleukin-1 signaling occurs exclusively via type 1 receptor. Proc Natl Acad Sci USA 1993; 90:6155-6159
16. 16 Greenfeder SA, Nunes P, Kwee L, et al. Molecular cloning and characterization of a second subunit of the interleukin-1 receptor complex. J Biol Chem 1995; 270:13757-13765
17. 17 Schreuder H, Tardif C, Trump-Kallmeyer S, et al. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 1997; 386:194-200
18. 18 Danis VA, Millington M, Hyland VJ, et al. Cytokine production by normal human monocytes: inter-subject variation and relationship to an interleukin-1 receptor antagonist (IL-1ra) gene polymorphism. Clin Exp Immunol 1995; 99:303-310
19. 19 Miller LC, Lynch EA, Isa S, et al. Balance of synovial fluid, IL-1 β and IL-1 receptor antagonist in recovery from Lyme arthritis. Lancet 1993; 341:146-147
20. 20 Wilkinson RJ, Patel P, Llewelyn M, et al. Influence of polymorphism in the genes of interleukin-1 receptor antagonist and IL-1β on tuberculosis. J Exp Med 1999; 189:1863-1873
21. 21 Fang XM, Schröder S, Hoeft A, et al. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999; 27:1330-1334
22. 22 Russel DA, Tucker KK, Khinookoswong N, et al. Combined inhibition of interleukin-1 in tumor necrosis factor in rodent endotoxemia: improved survival and organ function. J Infect Dis 1995; 171:1528-1538
23. 23 Aiura K, Gelfand JA, Burke JF, et al. Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits. Infect Immun 1993; 61:3342-3350
24. 24 Opal SM, Fisher CF, Dhainaut J-F, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III randomized, double-blind, placebo-controlled multicenter trial. Crit Care Med 1997; 25:1115-1124
25. 25 Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41:2196-2204
26. 26 Brown MA, Hural J. Functions of IL-4 and control of its expression. Crit Rev Immunol 1997; 17:1-32
27. 27 Wang P, Wu P, Siegel ML, et al. Interleukin (IL)-10 inhibits nuclear factor κB (NF-κB) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995:9558-9563
28. 28 te Velde AA, Huijbens RJF, de Vries JE, et al. Interleukin-4 (IL-4) inhibits secretion of IL-1β, tumor necrosis factor α, and human IL-6 by human monocytes. Blood 1990; 76: 1392-1397
29. 29 Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77:1859-1870
30. 30 Vannier E, Miller MC, Dinarello CA. Coordinated anti-inflammatory effects of interleukin4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992; 89:4076-4080
31. 31 Hart PH, Vitti GF, Burgess DR, et al. Potential anti-inflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 1989; 86:3803-3807
32. 32 Jain-Vora S, LeVine AM, Chroneos Z, et al. Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa. Infect Immun 1998; 66:4229-4236
33. 33 Hultgren O, Kopf M, Tarkowski A. Staphylococcus aureus-induced septic arthritis and septic death is decreased in IL-4-deficient mice: role of IL-4 as promoter for bacterial growth. J Immunol 1998; 160:5082-5087
34. 34 Toi M, Harris AL, Bicknell R. Interleukin-4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun 1991; 174:1287-1293
35. 35 Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism of the antitumor effect of IL-4. Science 1992; 257:548-551
36. 36 Toi M, Bicknell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992; 52:275-279
37. 37 Vokes EE, Figlin R, Hochster H, et al. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer. Cancer J Sci Am 1998; 4:46-51
38. 38 Barton BE. IL-6: insights into novel biological activities. Clin Immunol Immunopathol 1997; 85:16-20
39. 39 Barton BE, Shortall J, Jackson JV. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun 1996; 64:714-718
40. 40 Libert C, Takahashi N, Cauwels A, et al. Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur J Immunol 1994; 24:2237-2242
41. 41 Xing Z, Gauldie J, Cox G, et al. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101:311-320
42. 42 Ruzek MC, Miller AH, Opal SM, et al. Characterization of early cytokine responses in an interleukin-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J Exp Med 1997; 185: 1185-1192
43. 43 Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83:113-118
44. 44 Lalani I, Bhoi K, Ahmed AF. Interleukin-10: biology, role in inflammation and autoimmunity. Ann Allergy 1997; 79:469-483
45. 45 Howard M, O'Garra A. Biological properties of interleukin-10. Immunol Today 1992; 13:198-200
46. 46 Opal SM, Wherry JC, Grint P. Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Clin Infect Dis 1998; 27:1497-1507
47. 47 Brandtzaeg P, Osnes L, Ovstebo R, et al. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med 1996; 184:51-60
48. 48 Clarke CJP, Hales A, Hunt A, et al. IL-10 mediated suppression of TNF-α production is independent of its ability to inhibit NF-κB activity. Eur J Immunol 1998; 28:1719-1726
49. 49 Gérard D, Bryns C, Marchant A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177:547-550
50. 50 Marchant A, Bruyns C, Vandenabeele P, et al. Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994; 24:1167-1171
51. 51 Dickensheets HL, Freeman SL, Smith MF, et al. Interleukin-10 upregulates tumor necrosis factor receptor type II (p75) gene expression in endotoxin-stimulated human monocytes. Blood 1997; 90:4162-4171
52. 52 Joyce DA, Gibbons DP, Geen P, et al. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 1994; 24:2699-2705
53. 53 Marchant A, Deviere J, Byl B, et al. Interleukin-10 production during septicaemia. Lancet 1994; 343:707-708
54. 54 van der Poll T, de Waal Malefyt R, Coyle SM, et al. Anti-inflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997; 175:118-122
55. 55 Lehmann AK, Halstensen A, Sornes S, et al. High levels of interleukin-10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995; 63:2109-2112
56. 56 Westendorp RGJ, Langermans JAM, Hurizinga TWJ, et al. Genetic influence on cytokine production in fatal meningococcal disease. Lancet 1997; 349:170-173
57. 57 van Dissel JT, van Langevelde P, Westendorp RGJ, et al. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351:950-953
58. 58 Pajkart D, Camoglio L, Tiel-van Buul MCM, et al. Attenuation of pro-inflammatory response by recombinant human IL-10 in human endotoxemia: the effect of timing of rhIL-10 administration. J Immunol 1997; 158:3971-3977
59. 59 Dai W, Kohler G, Brombacher F. Both innate and acquired immunity to Listeria monocytogenes infections are increased in IL-10-deficient mice. J Immunol 1997; 158:2259-2267
60. 60 van der Poll T, Marchant A, Koeogh CF, et al. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996; 174:994-1000
61. 61 Greenberger MJ, Strieter RM, Kunkel SL, et al. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995; 155:722-729
62. 62 Kühn R, Löhler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-274
63. 63 Du XX, Williams DA. Interleukin-11: a multifunctional growth factor derived from the hematopoietic micro-environment. Blood 1994; 83:2023-2030
64. 64 Neddermann P, Graiziani R, Ciliberto G, et al. Functional expression of soluble interleukin-11 (IL-11) receptor α and stoichiometry of in vitro IL-11 receptor complexes with GP130. J Biol Chem 1996; 271:30986-30991
65. 65 Tepler I, Elias L, Smith JW, et al. A randomized-placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87:3607-3614
66. 66 Trepicchio WL, Wang L, Bozza N, et al. Interleukin-11 regulates macrophage effector function through the inhibition of nuclear factor-κB. J Immunol 1997; 159:5661-5669
67. 67 Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-vs-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998; 201:115-123
68. 68 Hermann JA, Hall MA, Maini RN, et al. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998; 41:1388-1397
69. 69 de Waal Malefyt R, Figdor CG, Huijbens R, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. J Immunol 1993; 151:6370-6381
70. 70 Zurawski G, de Vries JE. Interleukin 13, an interleukin-4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994; 15:19-26
71. 71 McKenzie AN, Li X, Largaespada DA, et al. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 1993; 150:5436-5444
72. 72 Callard RE, Matthews DJ, Hibbert L. IL-4 and IL-13 receptors: are they one and the same? Immunol Today 1996; 17:108-110
73. 73 Mijatovic T, Kruys V, Caput D, et al. Interleukin-4 and -13 inhibit tumor necrosis factor-α mRNA translational activation in lipopolysaccharide-induced mouse macrophages. J Biol Chem 1997; 272:14394-14398
74. 74 Di Santo E, Meazza C, Sironi M, et al. IL-13 inhibits TNF production but potentiates that of IL-6 in vivo and ex vivo in mice. J Immunol 1997; 159:379-382
75. 75 Muchamuel T, Menon S, Pisacane P, et al. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-α, IFN-γ, and IL-12 production. J Immunol 1997; 158:2898-2903
76. 76 Mulligan MS, Warner RL, Foreback JL, et al. Protective effects of IL-4, IL-10, IL-12, and IL-13 in IgG immune complex-induced lung injury: role of endogenous IL-12. J Immunol 1997; 159:3483-3489
77. 77 Lentsch AB, Czermak BJ, Bless NM, etal. NF-κB activation during IgG immune complex-induced lung injury: requirements for TNF-α and IL-1β but not complement. Am J Pathol 1998; 152:1327-1336
78. 78 Lentsch AB, Czermak BJ, Jordan JA, et al. Regulation of acute lung inflammatory injury by endogenous IL-13. J Immunol 1999; 162:1071-1076
79. 79 Norgaard P, Hougaard S, Spang-Thomsen M, et al. Transforming growth factor β and cancer. Cancer Treat Rev 1995; 21:367-403
80. 80 Kingsley DM. The TGF-βsuperfamily: new members, new receptors and new genetic tests of function in different organisms. Genes Dev 1994; 8:133-146
81. 81 Litterio JJ, Roberts AB. TGF-β: a critical modulator of immune cell function. Clin Immunol Immunopathol 1997; 84:244-250
82. 82 Roberts AB, Sporn MB. Differential expression of the TGF-β isoforms in embryogenesis suggests specific roles in developing and adult tissues. Mol Reprod Dev 1992; 32: 91-98
83. 83 Norgaard P, Damstrup L, Rygaard K, et al. Growth suppression by transforming growth factor-β1 of human small cell lung cancer cell lines is associated to expression of the type II receptor. Br J Cancer 1994; 69:802-808
84. 84 Jetten AM, Shirley JE, Stoner G. Regulation and proliferation and differentiation of respiratory tract epithelial cells by TGF-β. Exp Cell Res 1986; 167:539-549
85. 85 Santana A, Saxena B, Noble NA, et al. Increased expression of transforming growth factor β isoforms (β1, β2, β3) in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 1995; 13:34-44
86. 86 Roberts AB, Flanders KC, Kondaiah P, et al. Transforming growth factor-β biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. Recent Prog Horm Res 1988; 44:157-197
87. 87 Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992; 359:693-699
88. 88 van der Poll T, Jansen J, van Leenen D, et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993; 168:955-960
89. 89 Ertel W, Scholl FA, Galatti H, et al. Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis. Arch Surg 1994; 129:1330-1337
90. 90 van Deuren M, Frieling TM, van der ven-Jongekrijg J, et al. Plasma patterns of tumor necrosis factor-α and TNF soluble receptors during acute meningococcal infections and the effect of plasma exchange. Clin Infect Dis 1998; 26:918-923
91. 91 Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151:1548-1561
92. 92 Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animals model of Gram-negative sepsis. J Exp Med 1994; 180:2173-2179
93. 93 Van Zee KJ, Kohno T, Fisher E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factorα in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89:4845-4849
94. 94 Aizawa Y, Akita K, Taniai M, et al. Cloning and expression of interleukin-18 binding protein. FEBS Lett 1999; 445:338-342
95. 95 Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol 1998; 161:3400-3407
96. 96 Thomassen E, Bird TA, Renshaw BR, et al. Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrpl leads to activation of signaling pathways similar to those used by interleukin-1. J Interferon Cytokine Res 1998; 18:1077-1088
97. 97 Hoshino K, Tsutsui H, Kawai T, et al. Cutting edge: generation of IL-18 receptor-deficient mice; evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 1999; 62:5041-5044
98. 98 Kanakaraj P, Ngo K, Wu Y, et al. Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J Exp Med 1999; 189:1129-1138
99. 99 Spriggs MK. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol 1996; 14:101-130
100. 100 Ploegh HL. Viral strategies of immune evasion. Science 1998; 280:248-253
101. 101 Moore KW, Vieira P, Fiorentino DF, et al. Homology of cytokine synthesis inhibitory factor (IL-10) to Epstein-Barr virus gene BCRF1. Science 1990; 248:1230-1234
102. 102 Wilson M, Seymour R, Henderson B. Bacterial perturbation of cytokine networks. Infect Immun 1998; 66:2401-2409
103. 103 Goldie AS, Fearon KCHM, Ross JA, et al. Natural cytokine antagonists and endogenous anti-endotoxin core antibodies in sepsis syndrome. JAMA 1995; 274:172-177
104. 104 Girardin E, Roux-Lomberd P, Grau GE, et al. Imbalance between tumor necrosis factor-α and soluble TNF receptor concentration in severe meningococcaemia. Immunology 1992; 76:20-23
105. 105 Stüber F, Petersen M, Bokelmann F, et al. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24:381-384
106. 106 Mira J-P, Cariou A, Grall F, et al. Association of TNF2, a TNF-α promotor polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282:561-568
107. 107 Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon gamma receptor has susceptibility to mycobacterial infection. J Clin Invest 1998; 101:2364-2369
108. 108 Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and salmonella infections in interleukin-12 receptor-deficient patients. Science 1998; 280:1435-1438
109. 109 Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141-147